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Short chain fatty acids (SCFAs) are produced in the gut by
bacterial fermentation of poorly digested carbohydrates. A key
mediator of their actions is the G protein-coupled free fatty acid
2 (FFA2) receptor, and this has been suggested as a therapeutic
target for the treatment of both metabolic and inflammatory
diseases. However, a lack of understanding of the molecular
determinants dictating how ligands bind to this receptor has
hindered development.We have developed a novel radiolabeled
FFA2 antagonist to probe ligand binding to FFA2, and in com-
bination with mutagenesis and molecular modeling studies, we
define how agonist and antagonist ligands interact with the
receptor. Although both agonist and antagonist ligands contain
negatively charged carboxylates that interact with two key pos-
itively charged arginine residues in transmembrane domains V
and VII of FFA2, there are clear differences in how these inter-
actions occur. Specifically, although agonists require interac-
tion with both arginine residues to bind the receptor, antago-
nists require an interaction with only one of the two. Moreover,
different chemical series of antagonist interact preferentially
with different arginine residues. A homology model capable of
rationalizing these observations was developed and provides a
tool that will be invaluable for identifying improved FFA2 ago-
nists and antagonists to further define function and therapeutic
opportunities of this receptor.
Short chain fatty acids (SCFAs)4 are produced in large
amounts in the gut by microbial fermentation of poorly digest-
ible carbohydrates (1–3). The predominant products are ace-
tate (C2) and propionate (C3). SCFAs have pleiotropic effects in
the body, both locally in the gut and after absorption (1–3). A
broad range of these effects occurs subsequent to activation of
one or both of a pair of closely related SCFA-regulated G pro-
tein-coupled receptors (GPCRs). These are designated as the
free fatty acid 2 (FFA2) and free fatty acid 3 (FFA3) receptors
(4–7). Mapping of key residues that contribute to the function
of the SCFAs at both FFA2 and FFA3 demonstrated that muta-
tion of either of a pair of arginine residues, one in transmem-
brane domain (TMD) V at position 1805.39 (Ballesteros and
Weinstein (8) positional numbering system in superscript) and
the other in TMDVII at position 2557.35, eliminated the agonist
action of both C2 and C3 (9). Moreover, a pair of histidine
residues in TMDs IV and VI, at positions 1404.56 and 2426.55,
also played important roles in defining the binding pocket for
the SCFAs or their function (9, 10).
There is a degree of selectivity in rank-order of potency for
the SCFAs between FFA2 and FFA3 with FFA2 preferentially
activated by the shorter SCFAs (4, 5) and, in general, by short
carboxylic acids with sp2 or sp-hybridized-carbon atoms (11).
However, the selectivity is modest, and C3 is the most potent
SCFA on both receptors, limiting the ability to use SCFAs to
define the specific roles of FFA2 and FFA3 (12, 13). This is
compounded because the absolute potency of the SCFAs also
varies between human and rodent orthologs of the receptors
(13). As such, the availability of higher potency and selective
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synthetic agonists and antagonists would greatly assist efforts
to explore the specific function of FFA2 over FFA3. However,
few such ligands have been described to date (14, 15). The first
reported synthetic FFA2-selective agonists were a group of
phenylacetamides exemplified by 4-chloro--(1-methylethyl)-
N-2-thiazolylbenzeneacetamide (16–18). However, these clear-
ly did not share the same binding site as the SCFAs as they were
fully active at forms of FFA2 in which either Arg-1805.39 or
Arg-2557.35 was altered to alanine (16). They also increased the
observed potency of the SCFAs when co-added (16–18) and, as
such, acted as both allosteric agonists and positive allosteric
modulators of the SCFAs. In efforts to identify FFA2-selective
agonists that share the same binding site as the SCFAs and are
therefore orthosteric in action, we showed that (R)-3-benzyl-4-
(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxo-
butanoic acid (Cmp 1) is a relatively potent and highly selective
agonist of both hFFA2 and murine (m)FFA2 (10). Like the
SCFAs, this ligand contains a carboxylate function, and there-
fore, on this basis, it was not unexpected when the activity of
Cmp 1 was also shown to be lacking in either the R180A5.39 or
R255A7.35 mutants of hFFA2 (10).
The lack of function for Cmp 1 and the SCFAs at mutants
R180A5.39 or R255A7.35 has generally been taken to suggest that
the carboxylate of these ligands form ionic interactions with
these arginine residues, and therefore the lack of function
results from a lack of binding. However, as binding assays for
FFA2 have not been available, it has not been possible to
directly test this hypothesis. Therefore, in this study we have
developed a radioligand binding assay for FFA2 based on a
recently reported FFA2-selective antagonist, 4-[[(R)-1-(benzo-
[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-(3-
chlorobenzyl)amino]-butyric acid (GLPG0974) (19), and we
used this in combination with receptor mutation studies and
molecular modeling to define how agonist and antagonist
ligands interact with this receptor. Through this we demon-
strate that although both Arg-1805.39 and Arg-2557.35 are
required for agonist binding, only one of these residues is
required for high affinity antagonist binding.
Experimental Procedures
Materials and Compounds—FFA2 ligands Cmp 1 and
CATPB ((S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoro-
methyl)phenyl) butanoic acid) were synthesized as described
previously (10). MeCATPB (methyl (S)-3-(2-(3-chlorophenyl)-
acetamido)-4-(4-trifluoromethylphenyl)butanoate) is an inter-
mediate in the synthesis of CATPB (10). Racemic GLPG0974
(4-[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-
carbonyl]-(3-chlorobenzyl)amino]butyric acid) (19), Cmp 71
(4-(1-(benzo[b]thiophene-3-carbonyl)-2-methyl-N-(4-trifluoro-
methylbenzyl)azetidine-2-carboxamido)butanoic acid),
MeCmp 71 (methyl 4-(1-(benzo[b]thiophene-3-carbonyl)-2-
methyl-N-(4-trifluoromethylbenzyl)azetidine-2-carboxami-
do)butanoate), Cmp 42 (4-(1-(2-(benzo[b]thiophen-3-yl)acet-
yl)-N-(4-chlorobenzyl)-2-methylazetidine-2-carboxamido)bu-
tanoic acid), and MeCmp 42 (methyl 4-(1-(2-(benzo[b]-
thiophen-3-yl)acetyl)-N-(4-chlorobenzyl)-2-methylazetidine-2-
carboxamido)butanoate) were synthesized essentially as
described previously (19, 20). The identity and95% purity of
each compound was confirmed by NMR, HRMS, and HPLC.
Tissue culture reagents were from Invitrogen. Molecular
biology enzymes and reagents were from Promega. The radio-
chemical [35S]GTPS was from PerkinElmer Life Sciences.
[3H]GLPG0974 (129 MBq/ml) was a gift of AstraZeneca
(Molndal, Sweden). All other experimental reagents used were
from Sigma unless indicated otherwise.
Plasmids andMutagenesis—The hFFA2 ormFFA3 receptors
with enhanced yellow fluorescent protein (eYFP) fused to their
C termini were cloned into the pcDNA5/FRT/TO expression
vector as described previously (9, 10, 13). Site-directed mu-
tagenesis to generate the point mutations described was per-
formed according to the QuikChange method (Stratagene,
Cheshire, UK).
Cell Culture, Transfection, and Generation of Cell Lines—
HEK293T cells were used for experiments employing transient
heterologous expression. These cells were maintained in Dul-
becco’s modification of Eagle’s medium (DMEM) supple-
mentedwith 10% fetal bovine serum, 2mML-glutamine, and 1
penicillin/streptomycin mixture (Sigma) at 37 °C and 5% CO2.
Transfections were performed using polyethyleneimine, and
experiments were carried out 48 h after transfection. The
inducible lines are described as Flp-InTM T-Rex 293 cells by
Invitrogen. These cell lines were generated as described previ-
ously (10, 21) and maintained in DMEMwithout sodium pyru-
vate supplemented with 10% fetal bovine serum, 1 penicillin/
streptomycin mixture, 5 g/ml blasticidin, and 200 g/ml
hygromycin B. All experiments carried out using these cells
were conducted after a 24-h treatment with 100 ng/ml doxycy-
cline, unless otherwise stated, to induce expression of the
receptor construct of interest.
Bioluminescence Resonance Energy Transfer (BRET)-Arres-
tin-2 Recruitment Assay—HEK293T cells were co-transfected
at a 4:1 ratio with plasmids encoding an eYFP-tagged form of
the receptor construct of interest and a -arrestin-2 Renilla
luciferase (22, 23). Cells were transferred into white 96-well
microtiter plates at 24 h post-transfection. At 48 h post-trans-
fection, cells were washed, and the culture medium was
replaced with Hanks’ balanced salt solution immediately prior
to conducting the assay. To assess the inhibitory ability of pro-
spective antagonist ligands, test compounds were added to the
cells followed by incubation for 5 min at 37 °C. To measure
-arrestin-2 recruitment to the receptor, the Renilla luciferase
substrate coelenterazine h (Nanolight Tech, Pinetop, CA) was
added to a final concentration of 2.5 M, and cells were incu-
bated for a further 5 min at 37 °C. Next, an EC80 concentration
(where EC80 concentration is an 80% maximally effective con-
centration of an agonist ligand) of an appropriate agonist was
added, and cells were incubated for an additional 10 min at
37 °C. BRET resulting from receptor--arrestin-2 interaction
was assessed bymeasuring the ratio of luminescence at 535 and
475 nm using a PHERAstar FS plate reader fitted with the
BRET1 optic module (BMG Labtech, Aylesbury, UK).
Intracellular Ca2 Mobilization Assay—All Ca2 experi-
ments were carried out using Flp-InTM T-RExTM stable-induc-
ible cell lines (24, 25). Cells were plated at 70,000/well in black
96-well plates with a clear bottom and then allowed to adhere
Ligand Binding to Free Fatty Acid 2 Receptor
304 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 1•JANUARY 1, 2016
 at D
EF Consortium
 - U
niv Library of Southern D
enm
ark on M
ay 26, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
for 3–6 h. Doxycycline was then added at 100 ng/ml concen-
tration to induce receptor expression, and cells were main-
tained in culture overnight. Prior to the assay, cells were labeled
for 45 min with the calcium-sensitive dye Fura-2 AM and then
washed and incubated for 20 min with Hanks’ balanced salt
solution containing the indicated concentration of antagonist.
Fura-2 fluorescent emission at 510 nm resulting from 340 or
380 nm excitation was then monitored using a Flexstation
(Molecular Devices, Sunnyvale, CA) plate reader. Baseline fluo-
rescence was measured for 16 s; test compounds were then
added, and fluorescence was measured for an additional 74 s.
The baseline-subtracted maximum 340/380 nm ratio obtained
after the compound addition was used to plot concentration-
response data.
[35S]GTPS Incorporation Assay—Cell membranes were
generated as described previously (9) from Flp-InTM T-RExTM
cells either uninduced or treated with doxycycline (100 ng/ml
unless otherwise indicated) to induce expression of the recep-
tor construct of interest. [35S]GTPS binding assays (26, 27)
were performed in reactions with 5 g of cell membrane pro-
tein pre-incubated for 15 min at 25 °C in assay buffer (50 mM
Tris-HCl, pH 7.4, 10 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 1
M GDP, and 0.1% fatty acid-free bovine serum albumin) con-
taining the indicated concentrations of ligands. The reaction
was initiated with addition of [35S]GTPS at 50 nCi per tube,
and the reaction was terminated after 1 h of incubation at 25 °C
by rapid filtration through GF/C glass filters using a 24-well
Brandel cell harvester (Alpha Biotech, Glasgow, UK). Unbound
radioligand was removed from filters by washing three times
with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, and 10 mM
MgCl2), and [35S]GTPS binding was determined by liquid
scintillation spectrometry.
cAMP Assay—All cAMP experiments were performed using
Flp-InTM T-RExTM 293 cells able to express receptors of inter-
est in an induciblemanner. Experiments were carried out using
a homogeneous time-resolved FRET-based detection kit (Cis-
Bio Bioassays, Codolet, France) according to the manufactu-
rer’s protocol. Cells were plated at 2000 cells/well in low-vol-
ume 384-well plates. The ability of agonists to inhibit 1 M
forskolin-induced cAMP production was assessed following a
co-incubation for 30 min with agonist compounds, which was
preceded by a 15-min pre-incubation with antagonist to allow
for equilibration.
Extracellular-regulated Kinase 1/2 (ERK1/2) Phosphoryla-
tion Assays—Experiments were performed using a homogene-
ous time-resolved FRET-based detection kit (CisBio Bioassays)
according to the manufacturer’s protocol. Cells were plated at
15,000 cells/well in low-volume 384-well plates. After a 1-h pre-
incubation with antagonist, agonist was added for a further 30
min, and then ERK1/2 phosphorylation was measured.
Procedures Applicable to All Radioligand Binding Exper-
iments—All receptor radioligand binding experiments using
[3H]GLPG0974 were conducted in glass tubes, in binding
buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM
EDTA, pH 7.4). Membrane protein was generated from Flp-
InTM T-RExTM cells induced to express the receptor construct
of interest with 100 ng/ml doxycycline (unless otherwise
stated). Nonspecific binding of the radioligand was determined
in the presence of 10 M CATPB. After the indicated incuba-
tion period at 25 °C, bound and free [3H]GLPG0974 were sep-
arated by rapid vacuum filtration through GF/C glass filters
using a 24-well Brandel cell harvester (Alpha Biotech, Glasgow,
UK), and unbound radioligandwas washed from filters by three
washes with ice-cold PBS. After drying (3–12 h), 3 ml of Ultima
GoldTM XR (PerkinElmer Life Sciences) was added to each
sample vial, and radioactivity was quantified by liquid scintilla-
tion spectrometry. Aliquots of [3H]GLPG0974 were also quan-
tified to define the concentration of [3H]GLPG0974 added per
tube. In all experiments, total binding never exceeded more
than 10% of that added, avoiding complications associated with
free radioligand depletion (28).
[3H]GLPG0974 Association and Dissociation Kinetic Binding
Assay—[3H]GLPG0974 dissociation and association kinetic
binding assays were performed using a reverse time
protocol. To assess dissociation kinetics [3H]GLPG0974, at
approximately Kd concentration, was incubated with 5 g of
membrane protein for 1 h at 25 °C in binding buffer. To induce
radioligand dissociation, 10 M CATPB was added in a time-
staggered approach to capture 5–240-min time points. For
determination of association kinetics, [3H]GLPG0974 and
membrane protein were added simultaneously in a time-stag-
gered approach to determine 5–240-min time points. All sam-
ples were then processed simultaneously.
[3H]GLPG0974 Saturation and Competition Binding As-
says—To construct saturation binding isotherms, various con-
centrations of [3H]GLPG0974 were incubated with 5 g of
membrane protein potentially expressing the receptor con-
struct of interest. For [3H]GLPG0974 competition binding
assays, the radioligand at approximately Kd concentration and
varying concentrations of unlabeled ligand of choice were co-
added to 5 g of membrane protein. Incubations were per-
formed for 2 h at 25 °Cbefore analysis of the extent of binding of
[3H]GLPG0974.
Determination of the “On” and “Off” Rates of Unlabeled
Ligands throughMeasurement of Competition Binding Kinetics
of [3H]GLPG0974—The kinetic binding parameters of unla-
beled ligands were determined through assessment of the bind-
ing kinetics of [3H]GLPG0974, as described in more detail by
Refs. 29 and 30. Here, binding buffer, [3H]GLPG0974 (at an
approximateKd concentration of 10 nM), and three different con-
centrationsof competitor (1-, 3-, and10-fold theestimatedrespec-
tive Ki concentration) were added simultaneously to glass tubes.
At the indicated time points, membrane protein was added, and
tubeswere gently agitated.Threedifferent concentrationsof com-
petitorwere assessed to ensure that the rate parameters calculated
were independent of ligand concentration.
Data Analysis and Curve Fitting—All data presented repre-
sent means  S.E. of at least three independent experiments.
All data analysis and curve fitting were carried out using the
GraphPad Prism software package version 5.0b (GraphPad, San
Diego). In the case of functional assays, concentration-response
data were plotted on a log axis, where the untreated vehicle
control conditionwas plotted at 1 log unit lower than the lowest
test concentration of ligand and then fitted to three-parameter
sigmoidal concentration-response curves. Statistical analysis of
curve fit parameters was carried out by independently fitting
Ligand Binding to Free Fatty Acid 2 Receptor
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the data from triplicate experiments and comparing the result-
ing curve fit values by t test or one- or two-way analysis of
variance followedbyBonferroni, Dunnett’s, orTukey’s post hoc
tests as appropriate. Antagonism experiments carried out with
multiple defined concentrations of antagonist were fit, where
appropriate, to a global Gaddum/Schild EC50 shift equation to
estimate pA2 values for the antagonist. In case of radioligand
dissociation and association kinetic binding assays, the dissoci-
ation data were fit to a dissociation (one-phase exponential
decay) model, and the association data were fit to a one-phase
association model depending on the koff value determined in
parallel experiments and the measured concentration of
[3H]GLPG0974 used. To generate saturation binding curves,
the specific binding versus radioligand concentration was fit to
a one-site specific binding model using GraphPad Prism 5, and
Bmax and Kd values for radioligand at wild type and mutant
receptors were calculated. To determine the affinity of unlabeled
ligands in termsofKi values, displacement assay datawere fit to an
inverse three-parameter sigmoidal one-site Ki value fit with the
measured radioligand concentration and affinity to the respective
receptor as constraints. To determine the kon and koff values of
unlabeled ligands through competition binding kinetics of
[3H]GLPG0974, data were fit globally using the kinetics of com-
petitivebindingequationavailable fromGraphPadPrism,with the
kon (1.730  106 M1 min1) and koff (0.014 min1) values of
[3H]GLPG0974 entered as constraints.
Homology Modeling—Homology modeling of the hFFA2
receptor was performed using the hFFA1 receptor (Protein
Data Bank code 4PHU) as template (31).Manual alignmentwas
conducted using the SeaView software (32). Prior to alignment,
theT4 lysozyme fusion protein construct inserted into the third
intracellular loop of hFFA1 was deleted, and the final template
was optimized using Protein Preparation Wizard (34), assign-
ing bond orders and partial charges, adding hydrogen atoms,
and deleting water molecules. Hydrogen bond assignment was
performed at pH 7.0 using PROPKA (33). Restrained minimi-
zation until heavy atoms converged to a rootmean square devi-
ation of 0.3 Å was executed using the OPLS-2005 force field
(35). The homology model of hFFA2 was constructed using
Prime’s homology modeling module (Prime, version 3.3,
Schrödinger, LLC, New York). Mutant receptors were gener-
ated. Restrained minimization of the final structures was per-
formed using OPLS-2005 force field in Protein Preparation
Wizard (35).
Ligand Preparation and Induced Fit Docking—Ligands were
prepared using the OPLS-2005 force field (35) in LigPrep (Lig-
Prep, version 2.7, Schrödinger, LLC). Ionization states were
generated using Epik at pH 7.0 2.0; only one low-energy ring
conformation per ligand was sampled (Epik, version 2.5,
Schrödinger, LLC). Induced-fit docking was performed using
the IFD 2006 protocol as implemented in the Schrodinger Suite
version 2013-1 (Glide version 5.9, Schrödinger, LLC; Prime ver-
sion 3.2, Schrödinger, LLC). Because hydrogen bonds between
Arg-2587.35 and Asn-2446.55 in the hFFA1/TAK-875 co-crystal
structure (31) are intact even with bound agonist, the equiva-
lent aligned His-2426.55 and Arg-2557.35 residues were not
refined during induced fit docking. Ligand conformational
sampling was conducted using default settings; initial Glide
docking was performed using standard settings; the maximum
number of poses per ligand was restricted to 20; and trimming
was allowed for Phe-87,His-140,Cys-141, Ile-145, Tyr-165, and
Val-179. Re-docking was executed in Glide using standard pre-
cision mode for the five highest ranking protein-ligand com-
plexes generated in the initial docking, which was within 30
kcal/mol of the lowest energy protein-ligand complex. Residues
were refined within 5 Å of each ligand.
Results
GLPG0974 (Fig. 1) has recently been described as a selective
FFA2 receptor antagonist that is able to block C2-mediated
chemotaxis of human neutrophils (19). We synthesized this
compound and demonstrated that it was able to antagonize, in
a concentration-dependent manner, both C3 and Cmp 1-me-
diated activation of a formof hFFA2 that had beenC-terminally
tagged with enhanced yellow fluorescent protein (hFFA2-
eYFP). This was the case whether employing a BRET-based
-arrestin-2 recruitment assay (Fig. 2A), a Gq/11-dependent
[Ca2]imobilization (Fig. 2B), or a Gi/o-dependent [35S]GTPS
incorporation (Fig. 2C) assay. In each case, when employing
80% maximally effective concentrations of either C3 or Cmp 1,
Me
OH
O
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S
N N
O OH
O
Cl
N
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O
O
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NH
ORO
O
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N
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O
O
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O
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S Cl
Cmp 1 GLPG0974
CATPB: R=H
MeCATPB: R=Me
Cmp 71: R=H
MeCmp 71: R=Me
Cmp 42: R=H
MeCmp 42: R=Me
FIGURE 1. Structures of key ligands employed. The chemical structures of the key ligands used in the studies are shown as follows: C3; Cmp 1; GLPG0974;
CATPB; MeCATPB; Cmp 42; MeCmp 42; Cmp 71; and MeCmp 71.
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GLPG0974 displayed high and similar potency inhibition
against each of the agonists (Table 1). GLPG0974 was highly
selective for hFFA2, showing no inhibitory effect on C3-medi-
ated activation of the closely related SCFA receptor hFFA3 (Fig.
2D). However, as found previously for CATPB, another FFA2
antagonist (10), GLPG0974 displayed marked species selectiv-
ity and was unable to block the effects of either C3 or Cmp 1 at
mFFA2 (Fig. 2E).
In the presence of increasing concentrations of GLPG0974,
there was a requirement for higher concentrations of Cmp 1 to
produce interactions between -arrestin-2 and hFFA2-eYFP
(Fig. 3A). However, higher concentrations of Cmp 1 were able
to overcome the effect of GLPG0974 (Fig. 3A). This was also the
case for antagonism of the effects of Cmp 1 byCATPB (Fig. 3B).
Cmp 1 was also able to increase levels of phosphorylated
ERK1/2 (pERK1/2) in cells expressing hFFA2 (Fig. 3C). Here, a
rapid peak of activation, occurring within 5 min, was followed
by a decline in levels of pERK1/2 to a new plateau that was
maintained for at least 60min (Fig. 3C). To allow effective equil-
ibration between Cmp 1 and GLPG0974, pERK1/2 was mea-
sured 30min after addition of the ligands. As in the-arrestin-2
recruitment assay, increasing concentrations of GLPG0974
resulted in a requirement for higher concentrations of Cmp1 to
achieve the same level of effect (Fig. 3D). Both global Gaddum/
Schild EC50 shift non-linear regression analysis (Fig. 3D) and
presentation of the results as a Schild plot (slope 0.91  0.11)
(Fig. 3E) were consistent with GLPG0974 acting as a high affin-
ity (pA2 estimate 7.85  0.08), competitive and surmountable
antagonist of hFFA2. Therefore, this antagonist is likely to bind
at the orthosteric site of the receptor (10). Interestingly, despite
significant structural differences, the affinity estimate for
GLPG0974 was very similar to the pA2 value we obtained for
CATPB (7.76  0.13), the only other previously reported
orthosteric antagonist of hFFA2 (Fig. 3B).
To explore themode of binding of GLPG0974 inmore detail,
we employed a radiolabeled form of this compound. This
ligand, [3H]GLPG0974, displayed excellent characteristics as a
radiotracer. In membranes from Flp-InTM T-RExTM 293 cells
that had been induced to express hFFA2-eYFP [3H]GLPG0974
bound with high affinity (Kd 7.5 0.4 nM, mean S.E., n
4) in saturation equilibrium binding assays and with low non-
specific to total binding ratios (Fig. 4A). Fitting of the data to
both 1-site and 2-site bindingmodels indicated no improved fit
to the 2-site model, and therefore, the data are fully consistent
with [3H]GLPG0974 binding to a single site on the receptor. As
anticipated from the lack of functional effects of GLPG0974 at
mFFA2 and hFFA3 (Fig. 2,D and E), [3H]GLPG0974 showed no
specific binding to membranes of Flp-InTM T-RExTM 293 cells
induced to express hFFA3-eYFP at concentrations up to 100 nM
(Fig. 4B), whereas in membranes induced to express mFFA2-
eYFP, a very low level of apparent specific binding was detected
(Fig. 4B), but useful analysis of the data was not possible as the
binding did not saturate, and best estimates predicted Kd150
nM. This was despite direct comparison of receptor expression,
based on eYFP fluorescence, indicating that each of these con-
structs was expressed in amounts similar to hFFA2-eYFP.
These preliminary studies allowed [3H]GLPG0974 to be
used in competition binding studies, which confirmed the
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FIGURE 2. GLPG0974 inhibits the actions of C3 and Cmp 1 at hFFA2. hFFA2-eYFP and -arrestin-2 Renilla luciferase were co-transfected transiently into
HEK293T cells. The capacity of GLPG0974 to inhibit interactions between hFFA2-eYFP and -arrestin-2 Renilla luciferase induced by an approximately EC80
concentrationof C3 (3mM) (filled symbols) or Cmp1 (10M) (open symbols) was then assessed (A). Flp-InTM T-RExTM293 cells stably harboringhFFA2-eYFP at the
Flp-InTM T-RExTM locus were induced to express the receptor. The capacity of GLPG0974 to inhibit elevation of [Ca2]i produced by EC80 concentrations of C3
or Cmp 1 is shown (B). Membranes from such induced cells were used to assess the ability of GLPG0974 to inhibit the binding of [35S]GTPS stimulated by EC80
concentrations of C3 (300M) and or Cmp 1 (1M) (C). Although C3 inhibited forskolin-induced cAMP production inmembranes of Flp-InTM T-RExTM 293 cells
induced to express hFFA3-eYFP, GLPG0974 did not inhibit this (D). Moreover, unlike at hFFA2, GLPG0974was unable to inhibit either C3 (filled symbols) or Cmp
1 (open symbols)-mediated inhibitionof forskolin-induced cAMPproduction inmembranes fromFlp-InTMT-RExTM293 cells induced toexpressmFFA2-eYFP (E).
TABLE 1
GLPG0974 inhibits both C3- and Cmp 1-mediated activation of hFFA2
pIC50 values forGLPG0974-mediated inhibition of the effect of EC80 concentrations
of either C3 or Cmp 1 in various functional assays were recorded. Data are mean
S.E.
Agonist
-Arrestin-2
BRET [Ca2]i [35S]GTPS
C3 7.43 0.03 7.46 0.22 6.74 0.18
Cmp 1 7.15 0.04 7.46 0.17 6.40 0.11
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FIGURE 3. Competitive and surmountable effects of GLPG0974 and CATPB versus Cmp 1. The capacity of varying concentrations of Cmp 1 to promote
interactions betweenhFFA2-eYFP and-arrestin-2Renilla luciferase in transiently transfectedHEK293T cells andhow thiswas alteredby the co-addition of the
indicated concentrations of either GLPG0974 (A) or CATPB (B) was assessed as in Fig. 2. In Flp-InTM T-RExTM 293 cells induced to express hFFA2-eYFP Cmp 1 (10
M) promoted phosphorylation of the ERK1/2 MAPKs above treatment with vehicle in a manner that was sustained over time (C). Following pre-treatment of
such cells with the indicated concentrations of GLPG0974, varying concentrations of Cmp 1 were added, and pERK1/2 levels were assessed 30 min later (D).
Data derived from experiments akin to those in D are also displayed as a Schild plot (E). This analysis was consistent with GLPG0974 acting as a competitive
antagonist of Cmp 1 and with affinity (pA2) 8.0 0.5.
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FIGURE 4. Characteristics of [3H]GLPG0974 binding towild type hFFA2. The capacity of various concentrations of [3H]GLPG0974 to bind tomembranes of
Flp-InTM T-RExTM 293 cells induced to express hFFA2-eYFP is displayed (A, circles). Parallel experiments performed in the presence of 10 M CATPB defined
nonspecific bindingof [3H]GLPG0974 (A, squares), whereas subtractionof nonspecific from total bindingdefined specific binding tohFFA2-eYFP (A, diamonds).
[3H]GLPG0974 at a concentration up to 90 nM showed no specific binding to membranes of Flp-InTM T-RExTM 293 cells induced to express hFFA3-eYFP (B),
whereas specific binding to mFFA2-eYFP was essentially linear over this concentration range and did not saturate (B). The capacity of varying concentrations
of GLPG0974, CATPB, Cmp 1, and C3 to compete for binding of [3H]GLPG0974 (10 nM) is shown (C). Association kinetics of the specific binding of 5.75 nM
[3H]GLPG0974 (D) and its subsequent dissociation (D) after addition of 10M CATPB at time 60min allowed independent assessment of the affinity of binding
of [3H]GLPG0974 to hFFA2 (see under “Results” for details).
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orthosteric nature of this ligand, because both the orthosteric
agonists, C3 and Cmp 1, were able to fully compete with
[3H]GLPG0974 to bind hFFA2 (Fig. 4C). This was also the case
for the antagonists CATPB and GLPG0974 (Fig. 4C). These
experiments also allowed determination of the affinity for each
displacing ligand. The two antagonists, CATPB (pKi  7.87 
0.08) and GLPG0974 (pKi  7.88  0.08), displayed almost
identical affinity (Table 2), although the affinity of Cmp 1 was
	10-fold lower (pKi  6.91  0.12). Furthermore, as antici-
pated from previous functional studies (9–11), C3 displayed
very modest affinity (pKi  2.96  0.11) at hFFA2.
[3H]GLPG0974 also proved useful in assessing the binding
kinetics of the ligand (Fig. 4D), indicating that its rate of
association was 1,730,000 74,000 M1 min1 (Fig. 4D), and
its rate of dissociation was 0.014  0.001 min1 (Fig. 4D).
Using these values to independently determine the affinity of
[3H]GLPG0974 yielded a Kd of 8.1 0.9 nM (mean S.E., n
3), a value similar to that obtained from the saturation binding
studies (Fig. 4A).
The FFA2 agonists C3 and Cmp 1 both contain a carboxylate
that is believed to be coordinated by two arginine residues, Arg-
1805.39 and Arg-2557.35, in the receptor. This is based on the
observation that both agonists lack function at individual ala-
nine mutants of either of these arginines (9, 10) and that
replacement of the carboxylate of Cmp 1 with either methyl
ester or tert-butyl ester groups also eliminated function (10).
Although no atomic level structure of FFA2 is currently avail-
able, in previously generated homology models (9), these resi-
dues are closely apposed (see below). Because we have found
both CATPB and GLPG0974 to also be orthosteric, and both
contain a carboxylate, a reasonable hypothesis was that this
moiety would bind in a similar manner for these antagonists as
it does for the agonists. Consistent with this hypothesis, high
affinity, specific binding of [3H]GLPG0974was lacking inmem-
branes from cells induced to express a double R180A5.39/
R255A7.35 mutant of hFFA2 (Fig. 5A). However, unexpectedly,
the single R180A5.39 and R255A7.35 mutant forms of hFFA2
each retained binding of [3H]GLPG0974 with only modest,
although statistically significant (p 
 0.001), reductions in
affinity (Fig. 5, B and C). Of note, the reduction in affinity was
more pronounced for the R180A5.39mutant comparedwith the
R255A7.35 variant (3-fold versus 1.7-fold), perhaps suggesting a
somewhat more important role for Arg-1805.39 in the binding
of this ligand. We also assessed the ability of [3H]GLPG0974 to
bind to eitherH140A4.56 (Fig. 5D) orH242A6.55 (Fig. 5E) hFFA2
mutants, as these residues are also known to play important
roles in FFA2 agonist binding and/or function (9, 10).
[3H]GLPG0974 bound effectively to both of thesemutants and,
in each case, with slightly higher affinity than to the wild type
hFFA2 construct (Fig. 5, D and E). To confirm that the lack of
specific binding of [3H]GLPG0974 to the dual R180A5.39/
R255A7.35 mutant of hFFA2-eYFP did not simply reflect lack of
expression, levels of eYFP fluorescence from membranes
expressing wild type and each hFFA2-eYFP mutant construct
were measured and compared (Fig. 5F). This confirmed that all
mutants were expressed and that specifically the R180A5.39/
R255A7.35 double mutant was expressed at levels comparable
with the wild type construct to which specific binding of
[3H]GLPG0974 could be measured effectively.
Because [3H]GLPG0974 retained affinity for each of the
orthosteric binding site singlemutants, this compound allowed
us to examine the importance of each of these residues in the
binding of other ligands to hFFA2. Initially, we explored the
ability of the agonists C3 (Fig. 6A) and Cmp 1 (Fig. 6B) to com-
pete with [3H]GLPG0974 to bind to each individual mutant.
These experiments demonstrated that each of the mutations
markedly reduced the affinity of both C3 and Cmp 1 as only
minimal competition could be observed even at the highest
agonist concentrations that could be employed (Fig. 6,A andB).
Such findings support the conclusion that the loss of function of
these agonists previously described at each of these mutations
(9, 10) results from a substantial reduction in binding affinity
and is not simply a loss of ability to activate the receptor.
In contrast, when we examined the ability of the antagonist
CATPB to compete with [3H]GLPG0974 at the single FFA2
mutants,muchmoremodest effects were observed (Fig. 6C and
Table 2). Indeed, no reduction in CATPB affinity was observed
for H140A4.56 and H242A6.55. Moreover, although both the
R180A5.39 (p
 0.001) and the R255A7.35 (p
 0.001) mutations
did produce statistically significant reduction in affinity, these
were still modest (7.8-fold at R255A7.35 and 3.5-fold at
R180A5.39) compared with the loss of affinity of the two ago-
nists at these mutants. Similar experiments were conducted
using GLPG0974 as competitor (Fig. 6D and Table 2). No sig-
nificant loss of affinity for GLPG0974 was observed at either
R255A7.35 or H242A6.55, whereas a significant (p 
 0.001)
increase in affinity was observed for H140A4.56. Notably, the
affinity of GLPG0974 was significantly reduced at R180A5.39
hFFA2 (p
 0.001), in this case by 5.5-fold (Fig. 6D andTable 2),
suggesting this residue is likely themost significant arginine for
GLPG0974 binding. These results, importantly, are consistent
with the saturation binding studies that also implicated Arg-
1805.39 as themore important of the two key arginine residues for
[3H]GLPG0974 binding. Taken together, analysis of the affinity of
GLPG0974 and CATPB at these mutants suggests that, despite
having similar overall affinity, there is a difference in which of the
two key arginine residues is most important for binding, Arg-
1805.39 for GLPG0974 versusArg-2557.35 for CATPB.
As we were surprised by the relatively minor effect of remov-
ing the positively charged arginine residues (at least individu-
ally) in hFFA2 on binding of the two antagonists, we next
addressed whether this reflected limited importance of the car-
boxylate functional group for binding of these antagonists. We
considered this primarily because in previous models of FFA2
TABLE 2
Estimated affinity of ligands at wild type and orthosteric binding
pocket mutants of FFA2, competition binding studies using
[3H]GLPG0974
The ability of CATPB and GLPG0974 to compete with [3H]GLPG0974 to bind to
wild type hFFA2 and each of the indicatedmutants of hFFA2 was assessed. Data are
presented as calculated affinity constant (pKi) values (mean S.E.). ***, p
 0.001.
One-way analysis of variance was followed by Dunnett’s test withWT as reference.
Receptor CATPB GLPG0974
WT 7.87 0.08 7.88 0.08
R255A7.35 6.98 0.06*** 7.59 0.09
R180A5.39 7.32 0.06*** 7.14 0.06***
H242A6.55 7.63 0.07 8.04 0.04
H140A4.56 7.99 0.09 8.56 0.10***
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agonist binding, the carboxylate functionality has generally
been predicted to form an ionic interaction with the key argi-
nine residues of the receptor (9, 10). Therefore, we synthesized
a variant of CATPB in which the carboxylic acid group was
replaced with a methyl ester (MeCATPB) (Fig. 1). At wild type
hFFA2 MeCATPB also functioned as an antagonist, able to
block the ability of C3 to promote recruitment of-arrestin 2 in
a concentration-dependent manner (Fig. 7A). However, the
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FIGURE5.Binding characteristics of [3H]GLPG0974 toorthostericbinding sitemutantsofhFFA2. Specific bindingof [3H]GLPG0974was assessed as in Fig.
4 in membranes from Flp-InTM T-RExTM 293 cells induced to express wild type or R180A5.39/R255A7.35 (RARA) (A), R180A5.39 (B), R255A7.35 (C), H140A4.56 (D), or
H242A6.55 (E) hFFA2-eYFP. Inserted values are ligand Kd S.E. No specific binding to R180A
5.39 R255A7.35 hFFA2-eYFP could be measured. Membranes from
cells expressing each of the forms above were assessed for relative levels of expression based on fluorescence corresponding to eYFP (F). RFU, relative
fluorescence units.
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FIGURE6.Agonist butnot antagonists of hFFA2 showmarkedly reducedability to completewith [3H]GLPG0974at receptorbinding sitemutants. The
capacity of C3 (A), Cmp 1 (B), CATPB (C), and GLPG0974 (D) to compete with [3H]GLPG0974 for binding to R180A5.39 (squares), R255A7.35 (triangles), H140A4.56
(inverted triangles), or H242A6.55 (diamonds) hFFA2-eYFP is shown. The effect of each ligand at wild type hFFA2-eYFP is illustrated by the broken lines.
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potency of MeCATPB to do so was significantly less than
CATPB (Fig. 7A). MeCATPB was also able to compete with
[3H]GLPG0974 for binding, but it did so with a 13-fold reduc-
tion in affinity (p
 0.01) compared with the carboxylate-con-
taining antagonist CATPB (Fig. 7B andTable 3). This reduction
in affinity appeared to result from a loss of ionic interaction
with the key arginine residues because, unlike forCATPB, there
was no significant decrease in affinity of MeCATPB at either
the R180A5.39 or R255A7.35 mutants compared with the wild
type receptor (Fig. 7C and Table 3). Indeed, at R255A7.35
MeCATPB displayed a modest trend, that was, however, not
statistically significant, toward an increase in affinity compared
with the wild type receptor (Fig. 7C and Table 3). This may
reflect that the substitution of Arg to Ala opens up the binding
pocket to allow more rapid access of this ligand (see below).
Next, to extend these analyses and to examine the importance
of the carboxylate to antagonists structurally related to
GLPG0974, we synthesized a carboxylate (Cmp 71)/methyl
ester (MeCmp 71) ligand pair (Fig. 1) based on a representative
compound in the GLPG0974 chemical series. These two com-
pounds both contain a p-trifluoromethylbenzyl moiety instead
of them-chlorobenzyl group of GLPG0974 (Fig. 1). MeCmp 71
also acted as an antagonist of C3 (Fig. 7D), and as with the
MeCATPB/CATPB pair, MeCmp 71 was significantly less
potent than Cmp 71 (Fig. 7D). As anticipated from the above
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FIGURE 7.Methyl esters of hFFA2antagonists display lower functional potency andaffinity than the corresponding carboxylates at hFFA2. The ability
of various concentrations of CATPB (filled symbols)/MeCATPB (open symbols) (A and B), of Cmp 71 (filled symbols)/MeCmp 71 (open symbols) (D and E), of Cmp
42 (filled symbols)/MeCmp42 (open symbols) (G andH) to inhibit C3-mediated interactions betweenhFFA2-eYFP and-arrestin-2-Renilla luciferase (A,D, andG)
or compete with [3H]GLPG0974 for binding towild type hFFA2-eYFP (B, E, andH) was assessed. The effects of R180A5.39 or R255A7.35 mutation on the ability of
MeCATPB (C) or MeCmp 71 (F) to compete with [3H]GLPG0974 to bind is also shown. The effect of each ligand at wild type hFFA2-eYFP is illustrated by the
broken lines.
TABLE 3
Estimatedaffinityof carboxylateandmethyl esterpairsof FFA2antag-
onists at wild type, R180A5.39, and R255A7.35 hFFA2
The ability of CATPB, MeCATPB, Cmp 71, and MeCmp 71 to compete with
[3H]GLPG0974 to bind to wild type (WT), R180A5.39, or R255A7.35 hFFA2 is shown.
Data are calculated affinity constant (pKi) values (mean S.E.). One-way analysis of
variance was followed by Dunnett’s test versusWT (*, p
 0.05; **, p
 0.01; p
 ***,
p
 0.001).
Receptor CATPB MeCATPB Cmp 71 MeCmp 71
WT 7.87 0.08 6.74 0.14a 7.39 0.04 6.22 0.09a
R255A7.35 6.98 0.06*** 7.08 0.10 7.06 0.09* 6.80 0.08**
R180A5.39 7.32 0.06** 6.52 0.14 7.01 0.10* 6.89 0.07**
a p
 0.001 for methyl ester versus carboxylate-containing antagonist at wild type.
Two-way analysis of variance with subsequent Bonferroni was used to compare
CATPB/Cmp 71.
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data, MeCmp 71 was also able to compete with [3H]GLPG0974
for binding to hFFA2, but it did so with significantly (p
 0.001)
reduced affinity (17-fold) compared with Cmp 71 (Fig. 7E and
Table 3). As with MeCATPB, there was no reduction of the
binding affinity of MeCmp 71 to either the R180A5.39 or
R255A7.35 hFFA2 single mutations compared with wild type
hFFA2, and indeed, there was a significant increase in affinity
(p 
 0.01) at both (Fig. 7F and Table 3). This further supports
the hypothesis that it is a loss of an ionic interactionwith one or
the other of these arginine residues that accounts for the
reduced affinity of themethyl ester derivatives. As a further test
of the contribution of the carboxylatemoiety to binding affinity
and function in this chemical series, we synthesized a further
carboxylate (Cmp 42)/methyl ester (MeCmp 42) pair from this
chemical series (Fig. 1) and performed both functional (Fig. 7G)
and binding studies (Fig. 7H). Once again, in both situations the
methyl ester was less effective than the carboxylate.
Having established that an ionic interaction with either Arg-
1805.39 or Arg-2557.35 contributes significantly to the binding
affinity of the hFFA2 antagonists, we next wished to establish
how these interactions affected binding affinity, i.e. whether
they were primarily altering binding on-rate or off-rate of these
ligands. For this, we used [3H]GLPG0974 to first establish bind-
ing kinetics for unlabeledGLPG0974 (Fig. 8A) andCATPB (Fig.
8B) at wild type hFFA2. These experiments demonstrated that
CATPB had both on- and off-rates that were greater than
GLPG0974, despite each compound having similar overall
affinity for wild type hFFA2 (Table 4), further demonstrating
differences in the mode of binding of these two antagonists
to hFFA2. To establish the contribution of the ionic interac-
tion to binding kinetics, we next compared the on- and off-rates
of Cmp 71 (Fig. 8C) with MeCmp 71 (Fig. 8D). Notably, the
reduction in affinity for MeCmp 71 was the result of a greater
than 10-fold decrease of the on-rate of this compound with
little change in off-rate (Table 4), suggesting that the electro-
static interaction primarily contributes to recruit the com-
pound into the binding pocket. By contrast, the lower affinity of
[3H]GLPG0974 to bind to both R180A5.39 and R255A7.35
hFFA2 largely reflected increases in the ligand off-rate from
these variants. This was particularly pronounced for the
R180A5.39 mutant that displayed more than 15-fold increase
(Table 5), suggesting that the interaction of the ligand carbox-
ylate with this binding pocket residue acts to hold the ligand
once initial engagement has taken place.
Finally, having observed key differences in binding between
agonists (require each of the Arg and His residues) and antag-
onists (require only a single Arg residue) and, indeed, between
the two different series of antagonists, which demonstrated a
preference for different Arg residues, we attempted to assess
whether molecular modeling studies could rationalize these
experimental observations. Models of hFFA2 were generated
based on the available atomic level structure of the closely
related receptor hFFA1 complexed to the allosteric partial ago-
nist ligand TAK-875 (Protein Data Bank code 4PHU) (31). Ini-
tially, docking studieswere carried out to explore possible bind-
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FIGURE 8. Effects on the binding kinetic of [3H]GLPG0974 demonstrate markedly different on and off rates for the antagonist series. The specific
binding of [3H]GLPG0974 (10 nM) to membranes of Flp-InTM T-RExTM 293 cells induced to expressed hFFA2-eYFP was assessed at a range of time points. The
studies were performed in the absence or presence of the indicated concentrations of either GLPG0974 (A) or CATPB (B). Visual analysis shows clearly that the
binding of [3H]GLPG0974 was slower in the presence of CATPB than in the presence of GLPG0974, reflecting the faster on rate kinetic of CATPB. Analysis as
shown previously (28, 29) allowed estimation of both on and off rates for the two antagonists (see under “Results” and Table 4 for details). C andD, equivalent
studies were performed with Cmp 71 (C) and MeCmp 71 (D) and illustrate the markedly slower on rate kinetic of the methyl ester of the pair (Table 4).
TABLE 4
Kinetic analysis of the binding of antagonist ligands to wild type
hFFA2
Ligand on and off rates were calculated from kinetic binding assays as illustrated in
Fig. 8. Data are means  S.E. n  4. Kd values (koff/kon) were assessed from these
values.
GLPG0974 CATPB Cmp 71 MeCmp 71
kon 1,220,000 87,000 6,360,000 1,540,000 398,000 16,200 26,900 9800
koff 0.021 0.002 0.094 0.026 0.016 0.001 0.011 0.007
Kd 17.2 0.6 nM 14.5 0.7 nM 39.9 1.7 nM 638 259 nM
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ing modes for the agonists C3 (Fig. 9A) and Cmp 1 (Fig. 9B).
Consistent with the experimental data indicating that agonists
require both Arg-1805.39 and Arg-2557.35 to bind, representa-
tive poses for both C3 and Cmp 1 enabled the agonists to form
electrostatic interactions with both of the arginine residues
simultaneously and to engage in hydrogen bonding interactions
with the conserved Tyr2386.51 (Fig. 9,A andB). In addition, this
model suggested that an interaction formed between His-
2426.55 and Arg-2557.35 that was important in positioning Arg-
2557.35 within the binding pocket (Fig. 9, A and B). This is con-
sistent with the finding that C3 and Cmp 1 display markedly
lower affinity for the H242A6.55 mutant (Fig. 6,A and B). More-
over,His-1404.56 andVal-1795.38, both ofwhich previously have
been reported to significantly reduce the potency of Cmp 1 in
functional assays (10), were found to be in proximity to the
phenyl group of Cmp 1 in the proposed binding pose (Fig. 9B).
Further validation for this model came from the observation
that it also predicted close proximity of Cmp 1 to several other
residues (Fig. 9B), including Tyr-903.33, Tyr-165ECL2, and Tyr-
2386.51, that, when mutated, alter the potency of the ligand in
functional assays (10).
Docking studies were then carried out for CATPB and
GLPG0974. These studies resulted in closely overlapping poses
for these two antagonists, despite their structural differences
(Fig. 10A). Interestingly, each compound appeared to form an
electrostatic interaction with mainly one of the two key Arg
residues. Specifically, GLPG0974 appeared to favor interaction
with Arg-1805.39, whereas CATPB favored interaction with
Arg-2557.35, observations seemingly supported by the relative
effects of mutation of each of these residues on the affinity of
the ligands in the binding studies (Table 2). Additional support
for the model was also provided when considering results with
the H242A6.55 mutant as, although the results did not reach
statistical significance, this mutation tended to reduce affinity
for CATPB but not GLPG0974 (Table 2). This observation is
R1805.39
  R2557.35
H2426.55
Y2386.51
BA
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FIGURE 9. Interaction of key orthosteric binding pocket residues with FFA2 agonists. Docking of C3 (A) or Cmp 1 (B) into a homology model of wild type
hFFA2 is illustrated. Representative binding poses show interactions with both Arg-1805.39 and Arg-2557.35, both of which residues are necessary for these
agonists tobindandactivatehFFA2. Themodels alsohighlight the contributionofHis-2426.55 for organizationof thebindingpocket for the carboxylateof each
agonist by interacting with Arg-2557.35. The docked binding mode of Cmp 1 is further supported by important amino acids (including Tyr-903.33, His-1404.56,
Tyr-165ECL2, Val-1795.38, and Tyr-2386.51), which in functional assays have been shown to affect the ability of Cmp 1 to activate hFFA2 (10). The inset to B shows
greater detail of ionic interactions. In particular, the Arg-255–His-242 dyad and the Arg-255–His-242–Tyr-94 triad are highlighted.
R2557.35
H2426.55
R180A5.39
R1805.39
H2426.55
  R2557.35
B CA
R255A7.35 R1805.39
H2426.55
FIGURE10.Selective interactionsofCATPBandGLPG0974withArg-1805. 39 andArg-2557.35.Representativeposes of CATPB (green) andGLPG0974 (cyan)
inhFFA2 (A) enabled ionic interactionsbetweenGLPG0974andArg-1805.39 andbetweenCATPBandArg-2557.35. The twoantagonists, originating fromdistinct
chemical series, attain similar poses despite their structural differences. In the pointmutant R255A7.35 hFFA2model, CATPB and GLPG0974were able to retain
similar docked binding poses as the ones observed in wild type hFFA2 while interacting electrostatically with Arg-1805.39 (B). In the point mutant R180A5.39,
both antagonists are now able to engage Arg-2557.35 (C).
TABLE 5
Kinetic analysis of thebindingof [3H]GLPG0974 toorthosteric binding
site mutants of hFFA2
One-way analysis of variance was followed by Dunnett’s test with WT as reference
(***,
 p
 0.001).
WT R180A5.39 R255A7.35
kon 1,730,000 74,000 6,794,000 3,388,000 3,480,000 167,000
koff 0.014 0.001 0.221 0.004*** 0.107 0.009***
Kd 8.1 0.9 nM 32.5 16.8 nM 30.7 4.1 nM
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entirely consistent with the notion that interactions between
His-2426.55 and Arg-2557.35 act to position and orient Arg-
2557.35 as the more important arginine residue for recognition
of CATPB.
These modeling results suggested that when only one of the
key arginine residues is mutated, a substantial loss of binding
affinity is not observed for the hFFA2 antagonists because
interaction with the second, less favorable, arginine may form
to compensate. To explore this hypothesis, we incorporated the
R255A7.35 mutation into the model and examined binding
poses of each antagonist (Fig. 10B). In doing so, we found that
both CATPB and GLPG0974 were able to retain similar orien-
tations within this mutant receptor as compared with their
binding pose in the wild type, each by forming an interaction
with the Arg-1805.39. Equivalent modeling of the R180A5.39
mutant (Fig. 10C) also indicated a capacity of the carboxylate of
both antagonists to now interact in a similar manner with Arg-
2557.35. This confirms, at least in themodel, that compensatory
interactions may occur with the remaining arginine if the other
is eliminated. Because Cmp 71 contains a p-trifluorometh-
ylbenzyl group in place of the m-chlorobenzyl found in
GLPG0974, we also modeled potential docking poses of this
ligand as a comparison (Fig. 11). Representative poses of Cmp
71 in hFFA2 were similar to those for GLPG0974 but enabled
ionic interactions with both Arg-1805.39 and Arg-2557.35.
Discussion
A thorough understanding of the basis of interactions
between smallmolecule ligands and their target proteins is cen-
tral to efforts in chemical biology. Moreover, in the case of
proteins that may be targets for the design of small molecule
ligands to treat disease, a detailed level of understanding is inte-
gral for designing selectivity over interactions with closely
related proteins and, potentially, to limit toxicity or other side
effects (36). GPCRs have been the most successfully targeted
group of proteins for therapeutic use. This focusmeans that for
family members that have attracted a great level of interest for
many years, such as receptors for adrenaline or for acetylcho-
line, a vast body of information is available on modes of ligand
binding. Indeed, in these cases atomic level structures of recep-
tors with bound agonist and/or antagonist ligands have largely
confirmed predictions developed over many years of studies
employing, for example, receptor mutagenesis (37–40). More-
over, the availability of a large number of ligands, often with
substantial compound series containing detailed structure-ac-
tivity information, has greatly facilitated understanding. How-
ever, even for relatively well characterized GPCRs, surprises in
the mode of binding of certain ligands have been produced
when atomic level structures have become available (31, 40).
There remain a large number of GPCRs for which no atomic
level structural information is available and where even ligand
pharmacology is extremely limited. In such cases, analysis of
the details of the ligand binding pocket(s) and the designed
development of improved ligands is exceptionally challenging.
In recent years, it has become clear that a number of GPCRs
are activated by ligands that are also metabolic intermediates
(41–44). The group of GPCRs that respond to SCFAs, includ-
ing C2 and C3, have been suggested to be potential therapeutic
targets in relation to both metabolic diseases (42–44) and, par-
ticularly, inflammatory conditions (1, 45, 46). Indeed, observa-
tions of the blockade of neutrophil chemotaxis by the FFA2
receptor antagonist GLPG0974 was taken as a useful, and
potentially prognostic, indicator of the potential of this com-
pound to improve lower gut inflammatory disorders, including
ulcerative colitis (19). This resulted in GLPG0974 being used in
“first in man” clinical trials of an FFA2 antagonist (19). As also
noted byRef. 19, we confirmed thatGLPG0974 had no ability to
block agonist effects at the other SCFAGPCR, FFA3.Moreover,
as we have also shown for CATPB (10), GLPG0974 displayed
substantial species selectivity and was unable to inhibit agonist
activation of mFFA2. As these species orthologs show modest
variation in regions close to the binding pocket for SCFAs then,
in the future, the availability of [3H]GLPG0974 should allow the
basis for these difference(s) to be probed via generation of a
variety of point mutations and species ortholog chimeras.
SCFAs, but not the corresponding amides, are agonists at
FFA2 (9). As such, the importance of the carboxylate in either
or both binding to or activation of the receptor is evident.
Indeed, that formic acid (C1) has some level of potency at FFA2
demonstrates that the carboxylic acid is the only necessary req-
uisite for activation of the receptor (11, 47, 48). A reliance
exclusively on functional end points cannot, however, separate
these possibilities. Initial analysis of the mode of binding of the
SCFAs focused on positively charged amino acids shared
between FFA2 and FFA3 that might interact with the carboxy-
late of the ligands (9). Mutation to alanine of either Arg-1805.39
or Arg-2557.35 in hFFA2 eliminated responses to the SCFAs (9)
leading to the conclusion that both were of equal importance.
Furthermore, this view was extended by the first report of a
synthetic orthosteric agonist of FFA2, Cmp 1, which also con-
FIGURE 11. Comparison of docked poses of Cmp 71 and GLPG0974 in
hFFA2. The two antagonists Cmp 71 (yellow) and GLPG0974 (cyan), originat-
ing from the same chemical series, attain similar docked poses within the
binding site of hFFA2. Representative poses of Cmp 71 and GLPG0974 in
hFFA2 enabled ionic interactions between GLPG0974 and Arg-1805.39 and
between Cmp 71 and both Arg-1805.39 and Arg-2557.35.
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tained a carboxylate moiety and also lacked function at both
R180A5.39 hFFA2 and R255A7.35 hFFA2 (10).
Key to the current reassessment of these conclusions was
synthesis of the hFFA2 radiotracer [3H]GLPG0974. Although
unable to bind with high affinity to the double mutant
R180A5.39/R255A7.35 hFFA2, this ligand did bind to both the
R180A5.39 and R255A7.35 hFFA2 single mutants with only
slightly reduced affinity compared with the wild type receptor.
This allowed the contribution of each of these positively
charged residues to be evaluated separately. Although rather
modest reduction in affinity was noted for both CATPB and
GLPG0974 at thesemutants, binding of agonist ligands, includ-
ing Cmp 1, which is relatively potent and displays affinity close
to 100 nM at wild type FFA2, was all but lost followingmutation
of either Arg-1805.39 or Arg-2557.35. This indicates that both of
these residues are integral to recognition of agonist ligands.
This is supported by the fact that the endogenous agonists of
this receptor are SCFAs and that the only currently reported
orthosteric agonists contain a carboxylate moiety. Revealingly,
mutation of His-2426.55 to Ala all but ablated agonist affinity at
hFFA2. Based on the atomic level structure of hFFA1 bound by
the agonist TAK-875 (31), a key role of the equivalent Asn-
2446.55 residue in FFA1 is to provide stabilization of the argi-
nine residue at position 7.35. Assuming this is also true in
hFFA2, then destabilization of the position of this Arg
(sequence position 255) would be consistent with the observed
loss of interaction and function of orthosteric agonists. Indeed,
this arrangement was observed between Arg-2557.35 and His-
2425.39 after induced fit docking without manual interference
or refinement of the residues.
Antagonists are defined by their capacity to bind to but lack
the ability to activate their target receptor. Although both
GLPG0974 and the previously described hFFA2 antagonist
CATPB contain a carboxylate, it had been unclear whether this
interacted with either or both Arg-1805.39/Arg-2557.35 and
whether this was integral to provide affinity. However, as
[3H]GLPG0974 could bind to both R180A5.39 and R255A7.35
hFFA2 variants with only rather modestly reduced affinity
compared with wild type, this seemed unlikely. To assess this
more directly and to define the contribution of the carboxylate
to binding affinity, we generated carboxylate and methyl ester
pairs of exemplars of the two described classes of FFA2 antag-
onists. Although there was a clear reduction in affinity of each
methyl ester at wild type FFA2 compared with the correspond-
ing carboxylate-containing ligand, this effect was in the region
of 10–15-fold, and no reduction in affinity for themethyl esters
versus the carboxylate was observed at R255A7.35 FFA2. Indeed,
the affinity of the methyl esters was slightly higher at this
mutant. This may possibly reflect opening up extra space in the
binding pocket by removing the size as well as the charge of the
arginine residue.
Although initial homology models that were used to predict
the mode of binding of the SCFAs to FFA2 indicated a contri-
bution of both Arg-1805.39 and Arg-2557.35 (9), the very small
size of the ligands and low potency limited significantly further
consideration. As such, even though the ligands remained small
and displayed poor potency, the identification of a series of
small carboxylic acids that activate FFA2 with significant selec-
tivity over FFA3 (11), coupled with further mutagenesis studies
(11), resulted in a clearer understanding of the orthosteric bind-
ing pocket of the receptor. This was further enhanced by syn-
thesis and testing of the first described selective andmoderately
potent orthosteric agonists of hFFA2, including Cmp 1 used
herein (10). Key interactions of the carboxylate of this ligand
with both Arg-1805.39 and Arg-2557.35 were both predicted and
verified as Cmp 1 lacked function after mutation of either of
these residues. However, although usedwithin the same studies
as Cmp 1, the potential basis of binding of the antagonist
CATPB was not modeled at that stage. At least in part, this
reflected a lack of availability of a radiolabeled FFA2 antagonist
with which to assess ligand binding and effects of receptor
mutations on ligand affinity directly. Moreover, at the time of
these early studies, no atomic level structure of a GPCR closely
related to FFA2was available, and therefore,models were based
on the 2-adrenoreceptor inactive state structure (49). The rel-
atively high similarity of FFA2 to FFA1, for which a crystal
structure with a bound agonist has recently become available
(31), provided a much more suitable template for homology
modeling. In the FFA1 structure, the hydrogen-bonding net-
work defined by residues Glu-172 (within extracellular loop 2),
Arg-2587.35, and Asn-2446.55 is intact even with the agonist
TAK-875 bound to the receptor (31). Therefore, an equivalent
hydrogen-bonding network is presumed to exist in hFFA2
between Glu-166 (equivalent to Glu-172 in FFA1)–Arg-2557.35
(equivalent to Arg-2587.35) and His-2426.55 (equivalent to Asn-
2446.55). In the homology model His-2426.55, in concert with
Glu-166ECL2, fixes and restricts Arg-2557.35 in the orthosteric
site of hFFA2. In hFFA1, Asn-2446.55 is further directed by a
hydrogen bond to Ser-1875.43. In hFFA2, Ser-187 corresponds
to the poor hydrogen bond acceptor Cys-1845.43, and the ho-
mology model indicates that the directing role is taken over by
Tyr-943.37. These important observations might play a critical
role with respect to selectivity and binding of agonists and
antagonists in this receptor.
Docking of Cmp 1 into the hFFA2model resulted in a repre-
sentative pose suggesting possible interactions with Arg-
1807.35 and Arg-2557.35 simultaneously, both of which are nec-
essary for Cmp 1 to bind and activate hFFA2 (Fig. 9B) (10). Both
antagonists CATPB and GLPG0974 were able to interact with
both of the arginine residues in the orthosteric binding pocket
of hFFA2, and despite their structural differences, representa-
tive binding modes of the two antagonists appeared relatively
similar (Fig. 10A). These representative poses of CATPB and
GLPG0974 in hFFA2 enabled ionic interactions between
GLPG0974 and Arg-1805.39 and between CATPB and Arg-
2557.35. GLPG0974, having a longer more flexible carboxylate
chain with which it can interact electrostatically with the pre-
sumably more flexible Arg-1805.39, may partly explain the
observed reduced binding affinity of GLPG0974 (5.5-fold) to
R180A5.39 hFFAR2. This is contrary to CATPB (3.5-fold
decrease), which, having a shorter carboxylate chain, preferen-
tially interacts electrostatically with Arg-2557.35.
A further feature in the design of GPCR-targeted ligands that
has been attracting considerable attention in recent times is the
issue of ligand residence time (1/koff) (50). The dwell time of a
non-covalently bound ligand on a receptor can influence fea-
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tures such as ligand clearance and metabolism and the dosing
schedule and frequency of use of a medicine (50). It was thus of
interest to note that although CATPB and GLPG0974 have vir-
tually identical affinity at hFFA2, this is achieved in distinct
ways. Kinetic analysis of the binding of [3H]GLPG0974 in the
presence of differing concentrations of CATPB demonstrated
this antagonist to show both rapid association and dissociation
kinetics compared with GLPG0974, which was some 10-fold
slower than CATPB in both of these parameters. The slower
receptor binding kinetics of GLPG0974 may to some degree be
explained by its somewhat larger size and higher flexibility.
Although these are relativelymodest variations in ligand on and
off rates, the very slow off rate of the muscarinic M3 receptor
antagonist tiotropium has resulted in this ligand being a much
greater commercial success for the treatment of chronic
obstructive pulmonary disease than other M3 receptor antago-
nists of equivalently high affinity (51). Interestingly, by assess-
ing the binding kinetics of Cmp 71 compared with its methyl
ester, we established that somewhat surprisingly the ionic
interaction primarily contributed to the association rate of this
ligand. This indicates that the electrostatic interaction between
the carboxylate of Cmp 71 and the arginine residues primarily
contributes to recruit the compound and that it is less impor-
tant once the other receptor binding interactions have been
established. This is consistent with the observations that the
electrostatic interaction is dispensable for the activity of the
compound series and that one orthosteric arginine can substi-
tute for the other. It is also in line with the finding that on-rates
generally are more sensitive to modulation of the long range
electrostatic charges than off-rates (52).
These studies provide novel insights into the basis of agonist
and antagonist binding and are likely to provide guidance for
the generation of further and improved tool compounds. Given
the interest in targeting this receptor in both inflammatory (19)
and metabolic diseases (44, 53), they should assist in rapid
translation to assessment of such opportunities.
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